Platform

Reliable Cardiovascular Disease Models with Scientific Rigor and Reproducibility

KCI Biotech is an experienced cardiovascular CRO providing comprehensive in vivo pharmacology and efficacy services for drug discovery and preclinical development. We perform all experimental work under GLP-compliant management by professionally trained technical staff with extensive project experience. Our cardiovascular preclinical CRO capabilities are built to deliver scientific accuracy, safety, and reproducibility, supporting your pursuit of innovative therapies for cardiovascular and metabolic diseases.

Why Use Animal Models in Cardiovascular Research

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. Because many pathological processes cannot be fully replicated in vitro, animal models of cardiovascular disease are indispensable tools for understanding disease mechanisms, evaluating drug efficacy, and predicting clinical outcomes.

At KCI Biotech, our cardiovascular disease models are carefully developed and validated to simulate human pathological conditions, enabling translational studies that bridge preclinical findings to clinical reality.

Our Portfolio of Cardiovascular Disease Models

KCI Biotech provides a wide spectrum of cardiovascular models that cover multiple disease mechanisms, including ischemic injury, heart failure, hypertension, atherosclerosis, and so on. Each model is established using reproducible induction methods and standardized evaluation criteria.

Stroke Models

• Permanent Ischemic Stroke Model
• Ischemia-Reperfusion Stroke Model
• Photochemically Induced Ischemic Stroke Model
• Collagenase-Induced Hemorrhagic Stroke Model
• Sodium Laurate-Induced Cerebral Microvascular Injury Model

Acute Myocardial Infarction Models

• Acute Ischemia-Reperfusion Myocardial Infarction Model
• Acute Permanent Ischemic Myocardial Infarction Model

Heart Failure Models

• Heart Failure Induced by Myocardial Infarction
• Heart Failure Induced by Ascending Aortic Constriction
• Heart Failure Induced by Abdominal Aortic Constriction
• Heart Failure Induced by Pulmonary Aortic Constriction
• Deoxycorticosterone (DOCA) + High-Salt Induced Hypertensive Heart Failure Model

Additional cardiovascular disease models are available upon request. Custom modeling and tailored evaluation endpoints can be provided based on sponsor needs.

Why Choose KCI Biotech as Your Cardiovascular CRO Partner

1. Extensive Experience in Cardiovascular Pharmacology

As a cardiology CRO with a long-standing focus on cardiovascular research, KCI Biotech combines expertise in ischemic injury, heart failure, and vascular biology to support discovery and translational studies. Our team has deep experience with models for heart failure, atherosclerosis, hypertension, and myocardial infarction.

2. Advanced Imaging and Pathophysiological Evaluation Platforms

KCI Biotech integrates in vivo imaging, biochemical, histopathological, and molecular analyses to evaluate therapeutic efficacy across multi-level endpoints. This ensures data reliability and high translational relevance.

 3. Proven Partner for Global Pharmaceutical R&D

With over 1,000 domestic and international partnerships, KCI Biotech has established a strong reputation as a reliable CRO for cardiovascular trials. Our efficient communication, transparent data management, and rapid study turnaround make us a trusted partner for global clients.

Cooperate with KCI Biotech, Your Experienced Cardiovascular CRO

From model selection to data interpretation, KCI Biotech provides comprehensive cardiovascular preclinical CRO services that accelerate the development of safe and effective heart therapies.

Whether you’re working on heart failure, atherosclerosis, ischemic injury, or coronary disease, our validated animal models and experienced team ensure scientific accuracy and translational success.